← Leaderboards
John A Butera
Hager Biosciences, Llc
$6,697,966
Attributed
$6,697,966
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $5.6M · FY2013–24$10M$7.5M$5M$2.5M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$6,697,966 · 4
By mechanism
UF1$5,598,515 · 1
R43$1,099,451 · 3
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Series”
- Lawrence Corey · Fred Hutchinson Cancer Center$445,660,381
- Kiran Datta · Leidos Biomedical Research, Inc.$292,634,066
- David R. Weir · University Of Michigan At Ann Arbor$276,156,779
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$231,733,045
- Dennis R. Burton · Scripps Research Institute$199,946,411
- Joel A Lipkin · Four Points Technology, Llc$183,862,844
Research focus
SeriesAlzheimer&AposScaffoldSmall MoleculePublic Health RelevanceAttenuatedModalityResponseLeadPropertyIn VivoDesignPharmaceutical PreparationsInnovationPharmacologic SubstancePharmacophoreNeuronsEconomic BurdenMolecular TargetPermeabilityLigandsLibrariesMalignant NeoplasmsMedical
Grant awards (4)
Optimization of Novel Potassium Channel Kv1.3 Blockers with Potential as Alzheimer's Disease Therapeutics$499,968
R43 · FY2024 · AG · contact PI
Preclinical Development of Novel Dual OXR/KOR Antagonists for Treatment of Substance Use Disorder$5,598,515
UF1 · FY2021 · DA · contact PI
Multi-targeted Ligands to Treat Chronic Neuropathic Pain$224,995
R43 · FY2015 · NS · contact PI
Multi-targeted Countermeasures against Acute and Delayed Effects of OP Exposure$374,488
R43 · FY2013 · ES · contact PI